Home
Bjørn Tore Gjertsen's picture

Bjørn Tore Gjertsen

Professor
  • E-mailBjorn.Gjertsen@uib.no
  • Phone+47 55 97 29 68+47 415 66 248
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Selected publications
  • Reikvam, Håkon; Hovland, Randi; Forthun, Rakel Brendsdal; Erdal, Sigrid; Gjertsen, Bjørn Tore; Fredly, Hanne Kristin; Bruserud, Øystein. 2017. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer. 17:630: 1-13. doi: 10.1186/s12885-017-3620-y
  • Karjalainen, Riikka; Pemovska, Tea; Popa, Mihaela Lucia; Liu, Minxia; Javarappa, Komal K.; Majumder, Muntasir Mamun; Yadav, Bhagwan; Tamborero, David; Tang, Jing; Bychkov, Dmitrii; Kontro, Mika; Parsons, Alun; Suvela, Minna; Mayoral Safont, Mireia; Porkka, Kimmo; Aittokallio, Tero; Kallioniemi, Olli; McCormack, Emmet; Gjertsen, Bjørn Tore; Wennerberg, Krister; Knowles, Jonathan; Heckman, Caroline Akemi. 2017. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 130: 789-802. doi: 10.1182/blood-2016-02-699363
  • Gullaksen, Stein-Erik; Skavland, Jørn; Gavasso, Sonia; Tosevski, Vinko; Warzocha, Krzysztof; Dumrese, Claudia; Ferrant, Augustin; Gedde-Dahl, Thobias; Hellmann, Andrzej; Janssen, Jeroen; Labar, Boris; Lang, Alois; Majeed, Mohammed Waleed; Mihaylov, Georgi; Stentoft, Jesper; Stenke, Leif; Thaler, Josef; Thielen, Noortje; Verhoef, Gregor; Voglova, Jaroslava; Ossenkoppele, Gert; Hochhaus, Andreas; Hjorth-Hansen, Henrik; Mustjoki, Satu; Sopper, Sieghart; Giles, Francis; Porkka, Kimmo; Wolf, Dominik; Gjertsen, Bjørn Tore. 2017. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 102: 1361-1367. doi: 10.3324/haematol.2017.167080
  • Rajala, Hanna L.M.; El Missiry, Mohamed; Ruusila, Anniina; Koskenvesa, Perttu; Brümmendorf, Tim H.; Gjertsen, Bjørn Tore; Janssen, Jeroen; Lotfi, Kourosh; Markevärn, Berit; Olsson-Strömberg, Ulla; Stenke, Leif; Stentoft, Jesper; Richter, Johan; Hjorth-Hansen, Henrik; Kreutzman, Anna; Mustjoki, Satu. 2017. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 143: 1543-1554. doi: 10.1007/s00432-017-2378-6
  • Omsland, Maria; Bruserud, Øystein; Gjertsen, Bjørn Tore; Andresen, Vibeke. 2017. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-KB inhibition in acute myeloid leukemia (AML). OncoTarget. 8: 7946-7963. doi: 10.18632/oncotarget.13853
  • Sopper, Sieghart; Mustjoki, Satu; White, Deborah; Hughes, Timothy; Valent, Peter; Burchert, Andreas; Gjertsen, Bjørn Tore; Gastl, Günther; Baldauf, Matthias; Trajanoski, Zlatko; Giles, Frank; Hochhaus, Andreas; Ernst, Thomas; Schenk, Thomas; Janssen, Jeroen J.W.M.; Ossenkoppele, Gert J.; Porkka, Kimmo; Wolf, Dominik. 2017. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology. 35: 175-184. doi: 10.1200/JCO.2016.67.0893
  • Kotopoulis, Spiros; Stigen, Endre; Popa, Mihaela Lucia; Mayoral Safont, Mireia; Healey, Andrew; Kvåle, Svein; Sontum, Per; Gjertsen, Bjørn Tore; Gilja, Odd Helge; McCormack, Emmet. 2017. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. Journal of Controlled Release. 245: 70-80. doi: 10.1016/j.jconrel.2016.11.019
  • Kontro, Mika; Kumar, Anil; Majumder, Muntasir Mamun; Eldfors, Samuli; Parsons, Alun; Pemovska, Tea; Saarela, Janna; Yadav, Bhagwan; Malani, Disha; Fløisand, Yngvar; Höglund, Martin; Remes, Kari Juhani; Gjertsen, Bjørn Tore; Kallioniemi, Olli; Wennerberg, Krister; Heckman, Caroline Akemi; Porkka, Kimmo. 2017. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia. 31: 301-309. doi: 10.1038/leu.2016.222
  • Andresen, Vibeke; Erikstein, Bjarte Skoe; Mukherjee, Herschel; Sulen, Andre; Popa, Mihaela Lucia; Sørnes, Steinar; Reikvam, Håkon; Chan, Kok-Ping; Hovland, Randi; McCormack, Emmet; Bruserud, Øystein; Myers, Andrew G.; Gjertsen, Bjørn Tore. 2016. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death & Disease. 7:e2497: 1-14. doi: 10.1038/cddis.2016.392
  • Thielen, Noortje; Richter, Johan; Baldauf, Matthias; Barbany, Gisela; Fioretos, Thoas; Giles, Francis; Gjertsen, Bjørn Tore; Hochhaus, Andreas; Schuurhuis, Gerrit Jan; Sopper, Sieghart; Stenke, Leif; Thunberg, Sarah; Wolf, Dominik; Ossenkoppele, Gert; Porkka, Kimmo; Janssen, Jeroen; Mustjoki, Satu. 2016. Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy. Clinical Cancer Research. 22: 4030-4038. doi: 10.1158/1078-0432.CCR-15-2791
  • Sulen, Andre; Gjertsen, Bjørn Tore. 2016. Leukocyte p38 and p53 proteins after environmental exposure; variation, associations and applicability. Universitetet i Bergen.
  • Helland, Øystein; Popa, Mihaela Lucia; Bischof, Katharina; Gjertsen, Bjørn Tore; McCormack, Emmet; Bjørge, Line. 2016. The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLOS ONE. 11:e0158208. doi: 10.1371/journal.pone.0158208
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 243: 172-181. doi: 10.1016/j.jconrel.2016.10.007
  • Sulen, Andre; Gullaksen, Stein-Erik; Bader, Lucius; McClymont, David; Skavland, Jørn; Gavasso, Sonia; Gjertsen, Bjørn Tore. 2016. Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacological Research. 113: 216-227. doi: 10.1016/j.phrs.2016.08.018
  • Hjorth-Hansen, Henrik; Stentoft, Jesper; Richter, Johan; Koskenvesa, Perttu; Höglund, Martin; Dreimane, Arta; Porkka, Kimmo; Gedde-Dahl, Thobias; Gjertsen, Bjørn Tore; Gruber, Franz; Stenke, Leif; Myhr-Eriksson, Kristina; Markevärn, Berit; Lübking, Anna; Vestergaard, Hanne; Udby, Lene; Bjerrum, Ole Weis; Persson, Inger; Mustjoki, Satu; Olsson-Strömberg, Ulla. 2016. Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 30: 1853-1860. doi: 10.1038/leu.2016.121
  • Sulen, Andre; Lygre, Stein Håkon Låstad; Hjelle, Sigrun Margrethe; Hollund, Bjørg Eli; Gjertsen, Bjørn Tore. 2016. Elevated monocyte phosphorylated p38 in nearby employees after a chemical explosion. Scientific Reports. 6:29060. doi: 10.1038/srep29060
  • Leitch, Calum; Osdal, Tereza; Andresen, Vibeke; Molland, Maren Kristine Butler; Kristiansen, Silje Elisabeth; Nguyen, Nhi Xuan; Bruserud, Øystein; Gjertsen, Bjørn Tore; McCormack, Emmet. 2016. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. OncoTarget. 7: 8105-8118. doi: 10.18632/oncotarget.6991
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology. 34:e15703.
  • Gavasso, Sonia; Gullaksen, Stein-Erik; Skavland, Jørn; Gjertsen, Bjørn Tore. 2016. Single-cell proteomics: Potential implications for cancer diagnostics. Expert Review of Molecular Diagnostics. 16: 579-589. doi: 10.1586/14737159.2016.1156531
  • Kotopoulis, Spiros; Dimcevski, Georg Gjorgji; McCormack, Emmet; Postema, Michiel; Gjertsen, Bjørn Tore; Gilja, Odd Helge. 2016. Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: a phase I clinical trial. Journal of the Acoustical Society of America. 139: 2092-2092. doi: 10.1121/1.4950209
  • Engen, Caroline Benedicte Nitter; Hajjar, Ehsan; Gjertsen, Bjørn Tore. 2016. Development of personalized molecular therapy for acute myeloid leukemia. Current Pharmaceutical Biotechnology. 17: 20-29. doi: 10.2174/1389201016666150930115024
Academic article
  • Nepstad, Ina; Hatfield, Kimberley Joanne; Aasebø, Elise; Hernandez-Valladares, Maria; Brenner, Annette; Bartaula-Brevik, Sushma; Berven, Frode; Selheim, Frode; Skavland, Jørn; Gjertsen, Bjørn Tore; Reikvam, Håkon; Bruserud, Øystein. 2018. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. Expert opinion on therapeutic targets. 639-653.
  • Omsland, Maria; Pise-Masison, Cynthia A.; Fujikawa, Dai; Galli, Veronica; Fenizia, Claudio; Parks, Robyn Washington; Gjertsen, Bjørn Tore; Franchini, Genoveffa; Andresen, Vibeke. 2018. Inhibition of tunneling nanotube (TNT) formation and Human T-cell leukemia virus type 1 (HTLV-1) transmission by cytarabine. Scientific Reports. 1-17.
  • Bischof, Katharina; Knappskog, Stian; Stefansson, Ingunn; McCormack, Emmet; Trovik, Jone; Werner, Henrica Maria Johanna; Woie, Kathrine; Gjertsen, Bjørn Tore; Bjørge, Line. 2018. High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer. 1-10.
  • Jørgensen, Katarina Mariann; Mosleth, Ellen Færgestad; Liland, Kristian Hovde; Hopf, Nancy Brenna; Holdhus, Rita; Stavrum, Anne-Kristin; Gjertsen, Bjørn Tore; Kirkeleit, Jorunn. 2018. Gene expression response in peripheral blood cells of petroleum workers exposed to sub-ppm benzene levels. International Journal of Environmental Research and Public Health. 1-18.
  • Gjerde, Cecilie Gudveig; Mustafa, Kamal Babikeir Eln; Hellem, Sølve; Rojewski, Markus; Gjengedal, Harald; Yassin, Mohammed Ahmed Alamin Yousif; Feng, Xin; Skaale, Siren G; Berge, Trond Inge; Rosén, Annika; Shi, Xieqi; Ahmed, Aymen B; Gjertsen, Bjørn Tore; Schrezenmeier, Hubert; Layrolle, Pierre. 2018. Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial. . Stem Cell Research & Therapy. 1-15.
  • Rajala, Hanna L.M.; El Missiry, Mohamed; Ruusila, Anniina; Koskenvesa, Perttu; Brümmendorf, Tim H.; Gjertsen, Bjørn Tore; Janssen, Jeroen; Lotfi, Kourosh; Markevärn, Berit; Olsson-Strömberg, Ulla; Stenke, Leif; Stentoft, Jesper; Richter, Johan; Hjorth-Hansen, Henrik; Kreutzman, Anna; Mustjoki, Satu. 2017. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 1543-1554.
  • Omsland, Maria; Bruserud, Øystein; Gjertsen, Bjørn Tore; Andresen, Vibeke. 2017. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-KB inhibition in acute myeloid leukemia (AML). OncoTarget. 7946-7963.
  • Lowenberg, Bob; Pabst, Thomas; Maertens, Johan; Van Norden, Yvette; Biemond, Bart J; Schouten, Harry C; Spertini, Olivier; Vellenga, Edo; Graux, Carlos; Havelange, Violaine; De Greef, Georgine E; de Weerdt, Okke; Legdeur, Marie-Cecile J C; Kuball, Juergen; Van Marwijk Kooy, Marinus; Gjertsen, Bjørn Tore; Jongen-Lavrencic, Mojca; Van De Loosdrecht, Arjan A; Van Lammeren-Venema, Danielle; Hodossy, Beata; Breems, Dimitri A; Chalandon, Yves; Passweg, Jakob; Valk, Peter J. M.; Manz, Markus G; Ossenkoppele, Gert J. 2017. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood. 1636-1645.
  • Kotopoulis, Spiros; Stigen, Endre; Popa, Mihaela Lucia; Mayoral Safont, Mireia; Healey, Andrew; Kvåle, Svein; Sontum, Per; Gjertsen, Bjørn Tore; Gilja, Odd Helge; McCormack, Emmet. 2017. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. Journal of Controlled Release. 70-80.
  • Gullaksen, Stein-Erik; Skavland, Jørn; Gavasso, Sonia; Tosevski, Vinko; Warzocha, Krzysztof; Dumrese, Claudia; Ferrant, Augustin; Gedde-Dahl, Thobias; Hellmann, Andrzej; Janssen, Jeroen; Labar, Boris; Lang, Alois; Majeed, Mohammed Waleed; Mihaylov, Georgi; Stentoft, Jesper; Stenke, Leif; Thaler, Josef; Thielen, Noortje; Verhoef, Gregor; Voglova, Jaroslava; Ossenkoppele, Gert; Hochhaus, Andreas; Hjorth-Hansen, Henrik; Mustjoki, Satu; Sopper, Sieghart; Giles, Francis; Porkka, Kimmo; Wolf, Dominik; Gjertsen, Bjørn Tore. 2017. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 1361-1367.
  • Sopper, Sieghart; Mustjoki, Satu; White, Deborah; Hughes, Timothy; Valent, Peter; Burchert, Andreas; Gjertsen, Bjørn Tore; Gastl, Günther; Baldauf, Matthias; Trajanoski, Zlatko; Giles, Frank; Hochhaus, Andreas; Ernst, Thomas; Schenk, Thomas; Janssen, Jeroen J.W.M.; Ossenkoppele, Gert J.; Porkka, Kimmo; Wolf, Dominik. 2017. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology. 175-184.
  • Forthun, Rakel Brendsdal; Aasebø, Elise; Rasinger, Josef Daiel; Bedringaas, Siv Lise; Berven, Frode; Selheim, Frode; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2017. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. Journal of Proteomics. 32-41.
  • Karjalainen, Riikka; Pemovska, Tea; Popa, Mihaela Lucia; Liu, Minxia; Javarappa, Komal K.; Majumder, Muntasir Mamun; Yadav, Bhagwan; Tamborero, David; Tang, Jing; Bychkov, Dmitrii; Kontro, Mika; Parsons, Alun; Suvela, Minna; Mayoral Safont, Mireia; Porkka, Kimmo; Aittokallio, Tero; Kallioniemi, Olli; McCormack, Emmet; Gjertsen, Bjørn Tore; Wennerberg, Krister; Knowles, Jonathan; Heckman, Caroline Akemi. 2017. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 789-802.
  • Laukkanen, S; Grönroos, T; Pölönen, P; Kuusanmäki, H; Mehtonen, J; Cloos, J; Ossenkoppele, Gert; Gjertsen, Bjørn Tore; Bruserud, Øystein; Heckman, Caroline A.; Heinäniemi, M; Kontro, Mika; Lohi, O. 2017. In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. Blood Cancer Journal. 4 pages.
  • Kontro, Mika; Kumar, Anil; Majumder, Muntasir Mamun; Eldfors, Samuli; Parsons, Alun; Pemovska, Tea; Saarela, Janna; Yadav, Bhagwan; Malani, Disha; Fløisand, Yngvar; Höglund, Martin; Remes, Kari Juhani; Gjertsen, Bjørn Tore; Kallioniemi, Olli; Wennerberg, Krister; Heckman, Caroline Akemi; Porkka, Kimmo. 2017. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia. 301-309.
  • Reikvam, Håkon; Hovland, Randi; Forthun, Rakel Brendsdal; Erdal, Sigrid; Gjertsen, Bjørn Tore; Fredly, Hanne Kristin; Bruserud, Øystein. 2017. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer. 1-13.
  • Thielen, Noortje; Richter, Johan; Baldauf, Matthias; Barbany, Gisela; Fioretos, Thoas; Giles, Francis; Gjertsen, Bjørn Tore; Hochhaus, Andreas; Schuurhuis, Gerrit Jan; Sopper, Sieghart; Stenke, Leif; Thunberg, Sarah; Wolf, Dominik; Ossenkoppele, Gert; Porkka, Kimmo; Janssen, Jeroen; Mustjoki, Satu. 2016. Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy. Clinical Cancer Research. 4030-4038.
  • Andresen, Vibeke; Erikstein, Bjarte Skoe; Mukherjee, Herschel; Sulen, Andre; Popa, Mihaela Lucia; Sørnes, Steinar; Reikvam, Håkon; Chan, Kok-Ping; Hovland, Randi; McCormack, Emmet; Bruserud, Øystein; Myers, Andrew G.; Gjertsen, Bjørn Tore. 2016. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death & Disease. 1-14.
  • Mukherjee, Herschel; Chan, Kok-Ping; Andresen, Vibeke; Hanley, Mariah L.; Gjertsen, Bjørn Tore; Myers, Andrew G. 2015. Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 mediate the cellular localization of nucleophosmin and its aml-associated mutants. ACS Chemical Biology. 855-863.
  • Bruserud, Øystein; Reikvam, Håkon; Fredly, Hanne Kristin; Skavland, Jørn; Hagen, Karen Marie; Hoang, Tuyen; Brenner, Annette; Kadi, Amir; Astori, Audrey; Gjertsen, Bjørn Tore; Pendino, Frederic. 2015. Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. OncoTarget. 2794-2811.
  • Hjorth-Hansen, Henrik; Stenke, Leif; Söderlund, Stina; Dreimane, Arta; Ehrencrona, Hans; Gedde-Dahl, Thobias; Gjertsen, Bjørn Tore; Höglund, Martin; Koskenvesa, Perttu; Lotfi, Kourosh; Majeed, Mohammed Waleed; Markevärn, Berit; Ohm, Lotta; Olsson-Strömberg, Ulla; Remes, Kari; Suominen, Merja; Simonsson, Bengt; Porkka, Kimmo; Mustjoki, Satu; Richter, Johan. 2015. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006). European Journal of Haematology. 243-250.
  • Landskron, Johannes; Helland, Øystein; Torgersen, Knut Martin; Aandahl, Einar Martin; Gjertsen, Bjørn Tore; Bjørge, Line; Tasken, Kjetil. 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 337-347.
  • Sandtorv, Alexander Harald; Leitch, Calum; Bedringaas, Siv Lise; Gjertsen, Bjørn Tore; Bjørsvik, Hans-Rene. 2015. 4-alkylated silver-N-heterocyclic carbene (NHC) complexes with cytotoxic effects in leukemia cells. ChemMedChem. 1522-1527.
  • Hampson, Peter; Wang, Keqing; Ersvær, Elisabeth; McCormack, Emmet; Schüler, Julia; Fiebig, Heinz-Herbert; Gjertsen, Bjørn Tore; Bruserud, Øystein; Lord, Janet M. 2014. Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukemic compound PEP005 in primary AML cells. Oncoscience. 529-539.
  • Kotopoulis, Spiros; Dimcevski, Georg Gjorgji; Gjertsen, Bjørn Tore; Gilja, Odd Helge; McCormack, Emmet ; Postema, Michiel. 2014. Sonoporation: from the lab to human clinical trials. IEEE International Ultrasonics Symposium Proceedings. 846-849.
  • Kotopoulis, Spiros; Delalande, Anthony; Popa, Mihaela Lucia; Mamaeva, Veronika; Dimcevski, Georg Gjorgji; Gilja, Odd Helge; Postema, Michiel; Gjertsen, Bjørn Tore; McCormack, Emmet. 2014. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. Molecular Imaging and Biology. 53-62.
  • Li, Ling; Osdal, Tereza; Ho, Yinway; Chun, Sookhee; McDonald, Tinisha; Agarwal, Puneet; Lin, Allen; Chu, Su; Qi, Jing; Li, Liang; Hsieh, Yao-Te; Dos Santos, Cedric; Yuan, Hongfeng; Ha, Trung; Popa, Michaela; Hovland, Randi; Bruserud, Øystein; Gjertsen, Bjørn Tore; Kuo, Ya-Huei; Chen, Wenyong; Lain, Sonia; McCormack, Emmet; Bhatia, Ravi. 2014. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell. 431-446.
  • Aasebø, Elise; Vaudel, Marc; Mjaavatten, Olav; Gausdal, Gro; van der Burgh, Arthur Edward Emiel; Gjertsen, Bjørn Tore; Doskeland, Stein Ove; Bruserud, Øystein; Berven, Frode; Selheim, Frode. 2014. Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. Proteomics. 1971-1976.
  • Haaland, Ingvild; Opsahl, Jill Anette; Berven, Frode; Reikvam, Håkon; Fredly, Hanne Kristin; Haugse, Ragnhild; Thiede, Bernd; McCormack, Emmet ; Lain, Sonia; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2014. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer.
  • Helland, Øystein; Popa, Mihaela Lucia; Vintermyr, Olav Karsten; Molven, Anders; Gjertsen, Bjørn Tore; Bjørge, Line; McCormack, Emmet. 2014. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLOS ONE.
  • Kotopoulis, Spiros; Haugse, Ragnhild; Mujic, Maja; Sulen, Andre; Gullaksen, Stein-Erik; McCormack, Emmet ; Gilja, Odd Helge; Postema, Michiel; Gjertsen, Bjørn Tore. 2014. Evaluation of the effects of clinical diagnostic ultrasound in combination with ultrasound contrast agents on cell stress: Single cell analysis of intracellular phospho-signaling pathways in blood cancer cells and normal blood leukocytes. IEEE International Ultrasonics Symposium Proceedings. 1186-1190.
  • Gavasso, Sonia; Mosleth, Ellen Færgestad; Marøy, Tove Helene; Jørgensen, Katarina Mariann; Nakkestad, Hanne Linda; Gjertsen, Bjørn Tore; Myhr, Kjell-Morten; Vedeler, Christian A. 2014. Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. PLOS ONE.
  • Rizzieri, David A.; Vey, Norbert; Thomas, Xavier; Huguet-Rigal, Françoise; Schlenk, Richard F.; Krauter, Jürgen; Kindler, Thomas; Gjertsen, Bjørn Tore; Blau, Igor Wolfgang; Jacobsen, Tove Flem; Johansen, Malin; Bergeland, Trygve; Gianella-Borradori, Athos; Krug, Utz. 2014. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Leukemia and Lymphoma. 2114-2119.
  • Kloster, Martine Müller; Naderi, Elin Hallan; Haaland, Ingvild; Gjertsen, Bjørn Tore; Blomhoff, Heidi Kiil; Naderi, Soheil. 2013. cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases. International Journal of Oncology. 1815-1821.
  • Fredly, Hanne Kristin; Ersvær, Elisabeth; Kittang, Astrid Marta Olsnes; Tsykunova, Galina; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2013. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical Epigenetics.
  • Reikvam, Håkon; Kittang, Astrid Marta Olsnes; Melve, Guro Kristin; Mosevoll, Knut Anders; Bentsen, Pål Tore; Ersvær, Elisabeth; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2013. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Current Cancer Drug Targets. 30-47.
  • McCormack, Emmet ; Silden, Elisabeth; West, Richard M.; Pavlin, Tina; Micklem, David Robert; Lorens, James; Haug, Bengt Erik; Cooper, Michael E.; Gjertsen, Bjørn Tore. 2013. Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. Cancer Research. 1276-1286.
  • McCormack, Emmet ; Mujic, Maja; Osdal, Tereza; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2013. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. E34-E42.
  • Pemovska, Tea; Kontro, Mika; Yadav, Bhagwan; Edgren, Henrik; Eldfors, Samuli; Szwajda, Agnieszka; Almusa, Henrikki; Bespalov, Maxim M.; Ellonen, Pekka; Elonen, Erkki; Gjertsen, Bjørn Tore; Karjalainen, Riikka; Kulesskiy, Evgeny; Lagström, Sonja; Lehto, Anna; Lepistö, Maija; Lundan, Tuija; Majumder, Muntasir Mamun; Marti, Jesus M. Lopez; Mattila, Pirkko; Murumagi, Astrid; Mustjoki, Satu; Palva, Aino; Parsons, Alun; Pirttinen, Tero; Rämet, Maria E.; Suvela, Minna; Turunen, Laura; Västrik, Imre; Wolf, Maija; Knowles, Jonathan; Aittokallio, Tero; Heckman, Caroline A.; Porkka, Kimmo; Kallioniemi, Olli; Wennerberg, Krister. 2013. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discovery. 1416-1429.
  • Reikvam, Håkon; Nepstad, Ina; Sulen, Andre; Gjertsen, Bjørn Tore; Hatfield, Kimberley Joanne; Bruserud, Øystein. 2013. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opinion on Investigational Drugs. 551-563.
  • Mustjoki, Satu; Richter, Johan; Barbany, Gisela; Ehrencrona, Hans; Fioretos, Thoas; Gedde-Dahl, Thobias; Gjertsen, Bjørn Tore; Hovland, Randi; Hernesniemi, Sari; Josefsen, Dag; Koskenvesa, Perttu; Dybedal, Ingunn; Markevärn, Berit; Olofsson, Tor; Olsson-Strömberg, Ulla; Rapakko, Katrin; Thunberg, Sarah; Stenke, Leif; Simonsson, Bengt; Porkka, Kimmo; Hjort-Hansen, Henrik. 2013. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia. 1520-1526.
  • Øye, Ola Kristoffer; Jørgensen, Katarina Mariann; Hjelle, Sigrun Margrethe; Sulen, Andre; Ulvang, Dag Magne; Gjertsen, Bjørn Tore. 2013. Gel2DE-A software tool for correlation analysis of 2D gel electrophoresis data. BMC Bioinformatics. 5 pages.
  • Herfindal, Lars; Myhren, Lene Elisabeth; Gjertsen, Bjørn Tore; Doskeland, Stein Ove; Gausdal, Gro. 2013. Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen. BMC Cancer.
  • Silden, Elisabeth; Hjelle, Sigrun Margrethe; Wergeland, Line; Sulen, Andre; Andresen, Vibeke; Bourdon, Jean-Christophe; Micklem, David Robert; McCormack, Emmet ; Gjertsen, Bjørn Tore. 2013. Expression of TP53 isoforms p53 beta or p53 gamma enhances chemosensitivity in TP53(null) cell lines. PLOS ONE. 11 pages.
  • Bredholt, Therese; Ersvær, Elisabeth; Erikstein, Bjarte Skoe; Sulen, Andre; Reikvam, Håkon; Aarstad, Hans Jørgen; Johannessen, Anne Chr.; Vintermyr, Olav Karsten; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2013. Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. BMC Pharmacology & Toxicology. 13 pages.
  • Gausdal, Gro; Wergeland, Anita; Skavland, Jørn; Nguyen, Eric; Pendino, Frederic; ROUHEE, NAZANIN; McCormack, Emmet ; Herfindal, Lars; Kleppe, Rune; Havemann, Ursula; Schwede, Frank; Bruserud, Øystein; Gjertsen, Bjørn Tore; Lanotte, Michel; Ségal-Bendirdjian, Evelyne; Doskeland, Stein Ove. 2013. Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death & Disease.
  • McCormack, Emmet ; Adams, Katherine J.; Hassan, Namir J.; Kotian, Akhil; Lissin, Nikolai M.; Sami, Malkit; Mujic, Maja; Osdal, Tereza; Gjertsen, Bjørn Tore; Baker, Deborah; Powlesland, Alex S.; Aleksic, Milos; Vuidepot, Annelise; Morteau, Oliver; Sutton, Deborah H.; June, Carl H.; Kalos, Michael; Ashfield, Rebecca; Jakobsen, Bent K. 2013. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1-and LAGE-1-positive tumors. Cancer Immunology and Immunotherapy. 773-785.
  • Øye, Ola Kristoffer; Ulvang, Dag Magne; Jørgensen, Katarina Mariann; Hjelle, Sigrun Margrethe; Gjertsen, Bjørn Tore. 2012. Volume visualization for exploration of population trends in two-dimensional gel electrophoresis protein data. Computer-Based Medical Systems. 1-6.
  • McCormack, Emmet Martin; Haaland, Ingvild; Venås, Gurid; Forthun, Rakel Brendsdal; Huseby, Sjur; Gausdal, Gro; Knappskog, Stian; Micklem, David Robert; Lorens, James; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2012. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 910-917.
  • Hallenborg, Philip; Feddersen, Søren; Francoz, Sarah; Murano, Incoronata; Sundekilde, Ulrik; Petersen, R.K.; Akimov, Vyacheslav; Olson, M.V.; Lozano, Guillermina; Cinti, Saverio; Gjertsen, Bjørn Tore; Madsen, Lise; Marine, Jean-Christophe ; Blagoev, Blagoy; Kristiansen, Karsten. 2012. Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death and Differentiation. 1381-1389.
  • Hjelle, Sigrun Margrethe; Sulen, Andre; Øye, Ola Kristoffer; Jørgensen, Katarina Mariann; McCormack, Emmet Martin; Hollund, Eli Bjørg; Gjertsen, Bjørn Tore. 2012. Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting. Journal of Proteomics. 69-78.
  • Gavasso, Sonia; Gjertsen, Bjørn Tore; Anderssen, Endre; Myhr, Kjell-Morten; Vedeler, Christian A. 2012. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. Multiple Sclerosis. 1116-1124.
  • Reikvam, Håkon; Hatfield, Kimberley Joanne; Ersvær, Elisabeth; Hovland, Randi; Skavland, Jørn; Gjertsen, Bjørn Tore; Petersen, Kjell; Bruserud, Øystein. 2012. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. British Journal of Haematology. 468-480.
  • Oveland, Eystein; Wergeland, Line; Hovland, Randi; Lorens, James; Gjertsen, Bjørn Tore; Fladmark, Kari Espolin. 2012. Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biology and Toxicology. 201-212.
  • Fredly, Hanne Kristin; Reikvam, Håkon; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2012. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. American Journal of Hematology. 368-376.
  • Forthun, Rakel Brendsdal; Sengupta, Tanima; Skjeldam, Hanne Kim; Lindvall, Jessica Margareta; Mccormack, Emmet Martin; Gjertsen, Bjørn Tore; Nilsen, Hilde. 2012. Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLOS ONE.
  • Ånensen, Nina; Hjelle, Sigrun Margrethe; Van, Belle Werner; Haaland, Ingvild; Silden, Elisabeth; Bourdon, Jean-Christophe; Hovland, Randi; Tasken, Kjetil; Knappskog, Stian; Lønning, Per Eystein; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2012. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 1533-1545.
  • Skavland, Jørn; Jørgensen, Katarina Mariann; Hadziavdic, Kenan; Hovland, Randi; Jonassen, Inge; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2011. Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer Journal.
  • Fredly, Hanne Kristin; Ersvær, Elisabeth; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2011. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncology Reports. 1549-1556.
  • Erikstein, Bjarte Skoe; McCormack, Emmet Martin; Tronstad, Karl Johan; Schwede, Frank; Berge, Rolf Kristian; Gjertsen, Bjørn Tore. 2010. Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB. Leukemia Research. 77-84.
  • McCormack, Emmet Martin; Skavland, Jørn; Mujic, Maja; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2010. Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia. Nutrition and Cancer. 574-583.
  • Ersvær, Elisabeth; Liseth, Knut; Skavland, Jørn; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2010. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunology.
  • Hatfield, Kimberley Joanne; Bedringaas, Siv Lise; Ryningen, Anita; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2010. Hypoxia increases HIF-1 alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. European Cytokine Network. 154-164.
  • Fredly, Hanne Kristin; Bjørnsen, Camilla I. Stapnes; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2010. Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia - a report of five cases. Hematology. 338-343.
  • Erikstein, Bjarte Skoe; Hagland, Hanne; Nikolaisen, Julie; Kulawiec, Marion; Singh, Keshav K.; Gjertsen, Bjørn Tore; Tronstad, Karl Johan. 2010. Cellular stress induced by resazurin leads to autophagy and cell death via production of reactive oxygen species and mitochondrial impairment. Journal of Cellular Biochemistry. 574-584.
  • Gjerdrum, Christine; Tiron, Crina Elena; Høiby, Torill; Stefansson, Ingunn Marie; Haugen, Hallvard; Sandal, Tone; Collett, Karin; Li, Shan; McCormack, Emmet Martin; Gjertsen, Bjørn Tore; Micklem, David Robert; Akslen, Lars A.; Glackin, Carlotta A.; Lorens, James. 2010. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America. 1124-1129.
  • Semaeva, Elvira; Tenstad, Olav; Skavland, Jørn; Enger, Marianne; Iversen, Per Ole; Gjertsen, Bjørn Tore; Wiig, Helge. 2010. Access to the spleen microenvironment through lymph shows local cytokine production, increased cell flux, and altered signaling of immune cells during lipopolysaccharide-induced acute inflammation. Journal of Immunology. 4547-4556.
  • Olsnes, Astrid Marta; Ersvær, Elisabeth; Ryningen, Anita; Paulsen, Kristin; Hampson, Peter; Lord, Janet M.; Gjertsen, Bjørn Tore; Kristoffersen, Einar Klæboe; Bruserud, Øystein. 2009. The protein kinase C agonist PEP005 increases NF-kB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. British Journal of Haematology. 761-774.
  • Hatfield, Kimberley Joanne; Øyan, Anne Margrete; Ersvær, Elisabeth; Kalland, Karl-Henning; Lassalle, Philippe; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2009. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. British Journal of Haematology. 53-68.
  • Hatfield, Kimberley Joanne; Øyan, Anne Margrete; Ersvær, Elisabeth; Kalland, Karl-Henning; Lassalle, Philippe; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2009. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 53-68.
  • Reikvam, Håkon; Olsnes, Astrid Marta; Gjertsen, Bjørn Tore; Ersvær, Elisabeth; Bruserud, Øystein. 2009. Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. Critical reviews in oncogenesis. 1-41.
  • Oveland, Eystein; Gjertsen, Bjørn Tore; Wergeland, Line; Selheim, Frode; Fladmark, Kari Espolin; Hovland, Randi. 2009. Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells. Leukemia Research. 276-287.
  • Hofmann, Matthias; McCormack, Emmet Martin; Mujic, Maja; Roßberg, Maila; Bernd, August ; Bereiter-Hahn, Jürgen ; Gjertsen, Bjørn Tore; Wiig, Helge; Kippenberger, Stefan. 2009. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumour model. Neoplasia. 812-822.
  • Øyan, Anne Margrete; Ånensen, Nina; Bø, Trond Hellem; Stordrange, Laila; Jonassen, Inge; Bruserud, Øystein; Kalland, Karl-Henning; Gjertsen, Bjørn Tore. 2009. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer.
  • Gjertsen, Bjørn Tore. 2009. Er høyt hemoglobinnivå farlig? Tidsskrift for Den norske legeforening. 1881-1882.
  • Lukandu, Ochiba Mohammed; Bredholt, Therese; Neppelberg, Evelyn; Gjertsen, Bjørn Tore; Johannessen, Anne Chr.; Vintermyr, Olav Karsten; Costea, Daniela Elena. 2009. Early loss of mitochondrial inner transmembrane potential in khat-induced cell death of primary normal human oral cells. Toxicology. 108-116.
  • Bredholt, Therese; Dimba, Elisabeth Anne Okumu; Hagland, Hanne; Wergeland, Line; Skavland, Jørn; Fossan, Kjell O.; Tronstad, Karl Johan; Johannessen, Anne Chr.; Vintermyr, Olav Karsten; Gjertsen, Bjørn Tore. 2009. Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Molecular Cancer.
  • Ryningen, Anita; Stapnes, Camilla I; Lassalle, Philippe; Corbascio, Matthias A; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2009. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leukemia Research. 779-787.
  • Hatfield, Kimberley Joanne; Hovland, Randi; Øyan, Anne Margrete; Kalland, Karl-Henning; Ryningen, Anita; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2008. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia. 287-293.
  • Lukandu, Ochiba Mohammed; Costea, Daniela Elena; Dimba, Elisabeth Anne Okumu; Neppelberg, Evelyn; Bredholt, Therese; Gjertsen, Bjørn Tore; Vintermyr, Olav; Johannessen, Anne Chr. 2008. Khat induces G1-phase arrest and increased expression of stress-sensitive p53 and p16 proteins in normal human oral keratinocytes and fibroblasts. European Journal of Oral Sciences. 23-30.
  • Ryningen, Anita; Stapnes, Camilla I; Paulsen, Kristin; Lassall, Philippe; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2008. In vivo biological effects of ATRA in the treatment of AML. Expert Opinion on Investigational Drugs. 1623-1633.
  • Gausdal, Gro; Gjertsen, Bjørn Tore; McCormack, Emmet Martin; Van Damme, Petra; Hovland, Randi; Krakstad, Camilla; Bruserud, Øystein; Gevaert, Kris; Vandekerckhove, Joel; Doskeland, Stein Ove. 2008. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood. 2866-2877.
  • Stapnes, Camilla I; Døskeland, Anne Paulus; Hatfield, Kimberley Joanne; Ersvær, Elisabeth; Ryningen, Anita; Lorens, James; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology. 814-828.
  • Ersvær, Elisabeth; Hampson, Peter; Hatfield, Kimberley Joanne; Ulvestad, Elling; Wendelbo, Øystein; Lord, Janet M.; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. Cancer Immunology and Immunotherapy. 013-925.
  • Bruserud, Øystein; Ryningen, Anita; Olsnes, Astrid Marta; Stordrange, Laila; Øyan, Anne Margrete; Kalland, Karl-Henning; Gjertsen, Bjørn Tore. 2007. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 332-341.
  • Wergeland, Line; Sjøholt, Gry; Haaland, Ingvild; Hovland, Randi; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2007. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Molecular Cancer.
  • Huang, Tien-Sheng; Myklebust, Line Merethe; Kjærland, Endre; Gjertsen, Bjørn Tore; Pendino, Frederic; Bruserud, Øystein; Doskeland, Stein Ove; Lillehaug, Johan. 2007. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Molecular Cancer.
  • McCormack, Emmet Martin; Micklem, David Robert; Pindard, Lars Erik; Silden, Elisabeth; Gallant, Pascal; Belenkov, Alexandre; Lorens, James; Gjertsen, Bjørn Tore. 2007. In vivo optical Imaging of acute myeloid leukemia by green fluorescent protein: Time-domain autofluorescence decoupling, fluorophore quantification, and localization. Molecular Imaging. 193-204.
  • Bruserud, Øystein; Stapnes, Camilla I; Ersvær, Elisabeth; Gjertsen, Bjørn Tore; Ryningen, Anita. 2007. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Current Pharmaceutical Biotechnology. 388-400.
  • Stapnes, Camilla I; Ryningen, Anita; Hatfield, Kimberley Joanne; Øyan, Anne Margrete; Eide, Geir Egil; Corbascio, Matthias; Kalland, Karl-Henning; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukamia cells indentify patient subgroups that differ susceptibility to histone deactylase inhibitors. International Journal of Oncology. 1529-1538.
  • Irish, Jonathan C.; Ånensen, Nina; Hovland, Randi; Skavland, Jørn; Børresen-Dale, Anne-Lise; Bruserud, Øystein; Nolan, Gary P; Gjertsen, Bjørn Tore. 2007. Flt3 Y591 duplication and Bc1-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood. 2589-2596.
  • Ersvær, Elisabeth; Skavland, Jørn; Ulvestad, Elling; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunology and Immunotherapy. 13-24.
  • Ersvær, Elisabeth; Zhang, Jian-Ying; McCormack, Emmet Martin; Olsnes, Astrid Marta; Ånensen, Nina; Tan, Eng M.; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. European Journal of Haematology. 210-225.
  • Petersen, Kjell; Øyan, Anne Margrete; Rostad, Kari; Olsen, Sue; Bø, Trond Hellem; Salvesen, Helga; Gjertsen, Bjørn Tore; Bruserud, Øystein; Halvorsen, Ole Johan; Akslen, Lars A.; Steen, Vidar Martin; Jonassen, Inge; Kalland, Karl-Henning. 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 46-58.
  • Ersvær, Elisabeth; Hampson, Peter; Wendelbo, Øystein; Lord, Janet M.; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology. 199-207.
  • Øyan, Anne Margrete; Bø, Trond Hellem; Jonassen, Inge; Gjertsen, Bjørn Tore; Bruserud, Øystein; Kalland, Karl-Henning. 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. International Journal of Oncology. 1065-1080.
  • Ryningen, Anita; Ersvær, Elisabeth; Øyan, Anne Margrete; Kalland, Karl-Henning; Vintermyr, Olav Karsten; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2006. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2 : Bax ratio and low levels of heat shock protein 70 and 90. Leukemia Research. 1531-1540.
  • Sjøholt, Gry; Bedringaas, Siv Lise; Døskeland, Anne Paulus; Gjertsen, Bjørn Tore. 2006. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). Current Pharmaceutical Biotechnology. 159-170.
  • Bruserud, Øystein; Tronstad, Karl Johan; McCormack, Emmet Martin; Gjertsen, Bjørn Tore. 2006. Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia? Cancer Immunology and Immunotherapy. 221-228.
  • Belle, Werner Van; Ånensen, Nina; Haaland, Ingvild; Bruserud, Øystein; Høgda, Kjell-Arild; Gjertsen, Bjørn Tore. 2006. Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. BMC Bioinformatics. 198.
  • Krakstad, Camilla; Herfindal, Lars; Gjertsen, Bjørn Tore; Bøe, Roald; Vintermyr, Olav Karsten; Fladmark, Kari Espolin; Doskeland, Stein Ove. 2006. CaM-kinasell-dependent commitment to microcystin-induced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation. Cell Death and Differentiation. 1191-1202.
  • Van Belle, Werner; Sjøholt, Gry; Ånensen, Nina; Høgda, Kjell-Arild; Gjertsen, Bjørn Tore. 2006. Adaptive contrast enhancement of two-dimensional electrophoretic protein gel images facilitates visualization, orientation and alignment. Electrophoresis. 4086-4095.
  • Ånensen, Nina; Øyan, Anne Margrete; Bourdon, Jean-Christophe ; Kalland, Karl-Henning; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2006. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clinical Cancer Research. 3985-3992.
  • Sjøholt, Gry; Ånensen, Nina; Wergeland, Line; McCormack, Emmet Martin; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2005. Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 631-646.
  • Ryningen, Anita; Wergeland, Line; Glenjen, Nils; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2005. In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leukemia Research. 185-196.
  • Øyan, Anne Margrete; Bø, Trond Hellem; Jonassen, Inge; Ulvestad, Elling; Gjertsen, Bjørn Tore; Kalland, Karl-Henning; Bruserud, Øystein. 2005. CD34 expression in native human acute myelogenous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry. 18-27.
  • Irish, J.M.; Hovland, R.; Krutzik, P.O.; Perez, O.D.; Bruserud, Øystein; Gjertsen, Bjørn Tore; Nolan, G.P. 2004. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 217-228.
  • Berentsen, Sigbjørn; Ulvestad, Elling; Gjertsen, Bjørn Tore; Hjorth-Hansen, H.; Langholm, R.; Knutsen, H.; Ghanima, W.; Shammas, Fuad Victor; Tjønnfjord, G.E. 2004. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2925-2928.
  • Berentsen, Sigbjørn; Ulvestad, Elling; Gjertsen, Bjørn Tore; Hjorth-Hansen, Henrik; Langholm, Ruth; Knutsen, Håvar; Ghanima, Waleed; Shammas, Fuad Victor; Tjønnfjord, Geir E. 2004. Rituximab for pimary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2925-2928.
  • Bruserud, Øystein; Ryningen, Anita; Wergeland, Line; Glenjen, Nils; Gjertsen, Bjørn Tore. 2004. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica. 391-402.
  • Dimba, E.A.; Gjertsen, Bjørn Tore; Bredholt, Therese; Fossan, K.O.; Costea, Daniela-Elena; Francis, George W; Johannessen, Anne Chr.; Vintermyr, Olav Karsten. 2004. Khat (Catha edulis)-induced apoptosis is inhibited by antagonists of caspase-1 and -8 in human leukaemia cells. British Journal of Cancer. 1726-1726.
  • Gjertsen, Bjørn Tore; Bruserud, Øystein. 2004. How should clinical data be included in experimental studies of cancer immunology? Cancer Immunology and Immunotherapy. 677-680.
  • Ersvær, Elisabeth; Bertelsen, Liv-Turid; Espenes, Lars Christian; Bredholt, Therese; Bøe, Stig Ove; Iversen, Bjarne Magnus; Bruserud, Øystein; Ulvestad, Elling; Gjertsen, Bjørn Tore. 2004. Characterization of ribosomal P autoantibodies in relation to cell destruction and autoimmune disease. Scandinavian Journal of Immunology. 189-198.
  • Gausdal, Gro; Gjertsen, Bjørn Tore; Fladmark, Kari Espolin; Demol, H.; Vandekerckhove, Joel; Døskeland, Stein Ove. 2004. Caspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosis. Leukemia. 1989-1996.
  • Cimpan, Mihaela Roxana; Cressey, Lill Irene; Skaug, Nils; Halstensen, Alfred; Lie, Stein Atle; Gjertsen, Bjørn Tore; Matre, Roald. 2000. Patterns of cell death induced by eluates from denture base acrylic resins in U-937 human monoblastoid cells. European Journal of Oral Sciences. 59-69.
  • Bruserud, Øystein; Gjertsen, Bjørn Tore; von Volkman, Hilde L. 2000. In vitro Culture of Human Acute Myelogenous Leukemia (AML) Cells in Serum-Free Media: Studies of Native AML Blasts and AML Cell Lines. Journal of Hematotherapy & Stem Cell Research. 923-932.
  • Fladmark, Kari Espolin; Brustugun, Odd Terje; Hovland, Randi; Bøe, Ragnar; Gjertsen, Bjørn Tore; Zhivotovsky, B; Døskeland, Stein Ove. 1999. Ultrarapid apoptosis inducted by phosphatase inhibitors. Cell Death Differ. Cell Death and Differentiation. 1099-1108.
  • Jensen, PH; Fladmark, Kari Espolin; Gjertsen, Bjørn Tore; Vintermyr, Olav Karsten. 1999. Caspase I related protease inhibition retards the execution of okadaic acid and camptothecin induced apoptosis and PAI-2 selective cleavage, but not commitment to cell death in HL-60 cells. British Journal of Cancer. 1685-1691.
  • Austad, Joar; Bjerke, Jens Roar; Gjertsen, Bjørn Tore; Helland, Svein; Livden, John Karsten; Morken, Tore; Mørk, Nils-Jørgen. 1998. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology. 19-24.
  • Fladmark, Kari Espolin; Gjertsen, Bjørn Tore; Molven, Anders; Mellgren, Gunnar; Vintermyr, Olav Karsten; Døskeland, Stein Ove. 1997. Gap junctions and growth control in liver regeneration and in isolated rat hepatocytes. Hepatology. 847-855.
  • Fladmark, Kari Espolin; Gjertsen, Bjørn Tore; Døskeland, Stein Ove; Vintermyr, Olav Karsten. 1997. Fas/APO-1 (CD95)-Induced Apoptosis of Primary Hepatocytes Is Inhibited by cAMP. Biochemical and Biophysical Research Communications - BBRC. 20-25.
  • Gjertsen, Bjørn Tore. 1996. Kreftcellens skjulte veier til apotose. Kreftnytt.
  • Gjertsen, Bjørn Tore; Cressey, L. I.; Ruchaud, S.; Houge, G.; Lanotte, M.; Døskeland, Stein Ove. 1994. Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line. Journal of Cell Science, Supplement. 3363-3377.
  • Jensen, P. H.; Cressey, L.; Gjertsen, Bjørn Tore; Madsen, P.; Mellgren, Gunnar; Hokland, P.; Gliemann, J.; Døskeland, Stein Ove; Lanotte, M.; Vintermyr, Olav Karsten. 1994. Cleaved intracellular plasminogen activator inhibitor-2 is a marker of apoptosis present in human myeloid leukemia cells. British Journal of Cancer. 834-840.
  • Døskeland, Stein Ove; Maronde, E.; Gjertsen, Bjørn Tore. 1993. The genetic subtypes of cAMP-dependent protein kinase - functionally different or redundant? Biochimica et Biophysica Acta. 249-258.
  • Vintermyr, Olav Karsten; Gjertsen, Bjørn Tore; Lanotte, M.; Døskeland, Stein Ove. 1993. Microinjected catalytic subunit of cAMP-dependent protein kinase induces apoptosis in myeloid leukemic (IPC-81) cells. Exp Cell Res. 157-161.
  • Gjertsen, Bjørn Tore; Fauske, B.; Døskeland, Stein Ove. 1993. Exogenous substrate stimulate autodephosphorylation of cyclic-AMP-dependent protein kinase II. Biochemical Journal. 497-503.
  • Houge, G.; Døskeland, Stein Ove; Gjertsen, Bjørn Tore. 1993. Apoptotisk celledød. NBS-nytt. 6-12.
  • Houge, G.; Cressey, L. I.; Gjertsen, Bjørn Tore. 1993. Apoptosisk celledød - finnes det fornuft i fragmenteringen? NBS-nytt. 6-12.
  • Gjertsen, Bjørn Tore; Duprez, E.; Bernard, O.; Lanotte, M.; Døskeland, Stein Ove. 1993. Anti-apoptotic effect of heterozygously expressed mutant RI (Ala%3%3%6 ->Asp) subunit of cAMP-kinase I in a rat leukaemia cell line. Journal of Biological Chemistry. 8332-8340.
  • Bøe, Ragnar; Gjertsen, Bjørn Tore; Houge, G.; Vintermyr, Olav Karsten; Lanotte, M.; Døskeland, Stein Ove. 1991. The protein phosphatase inhibator okadaic acid induces morphological changes typical of apoptosis in mammalian cells. Experimental Cell Research. 237-246.
  • Lanotte, M.; Riviere, J. B.; Hermouet, S.; Houge, G.; Vintermyr, Olav Karsten; Gjertsen, Bjørn Tore; Døskeland, Stein Ove. 1991. Programmed cell death (apoptosis) is induced rapidly and with positive cooperativity by activation of cyclic adenosine monophosphate-kinase I in a myeloid leukemia cell line. Journal of Cellular Physiology. 73-80.
Academic lecture
  • Gjertsen, Bjørn Tore. 2017. Proteomics and single cell immune and signaling profiling of myeloid leukemia.
  • Kotopoulis, Spiros; Popa, Mihaela Lucia; Safont, MJ; Stigen, Endre; Healey, Andrew; Kvåle, Svein; Sontum, Per Chrisian; Gjertsen, Bjørn Tore; Gilja, Odd Helge; McCormack, Emmet. 2015. Sonoporation using Acoustic Cluster Therapy in combination With chemotherapy transiently reduces tumour volume.
  • Gjertsen, Bjørn Tore. 2013. Phosphoprotein signaling in acute myeloid leukemia.
  • Gjertsen, Bjørn Tore. 2007. Early protein and gene modulation in response to induction chemotherapy of acute myeloid leukemia.
  • Gjertsen, Bjørn Tore. 2007. Early Protein and Gene Modulation in Response to Induction Chemotherapy of Acute Myeloid Leukemia.
  • Øyan, Anne Margrete; Ånensen, Nina; Bø, Trond Hellem; Stordrange, Laila; Jonassen, Inge; Bruserud, Øystein; Kalland, Karl-Henning; Gjertsen, Bjørn Tore. 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • Øyan, Anne Margrete; Ånensen, Nina; Bø, Trond Hellem; Stordrange, Laila; Jonassen, Inge; Bruserud, Øystein; Kalland, Karl-Henning; Gjertsen, Bjørn Tore. 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • Bredholt, Therese; Dimba, Elisabeth Anne Okumu; Fossan, K.O.; Francis, George W; Johannessen, Anne Chr.; Vintermyr, Olav Karsten; Gjertsen, Bjørn Tore. 2005. Molecular mechanisms of apoptosis induced by khat extract and its alkaloids cathinone and cathine in acute myeloid leukemia.
  • Dimba, Elisabeth Anne Okumu; Bredholt, Therese; Costea, Daniela-Elena; Francis, George W; Johannessen, Anne Chr.; Vintermyr, Olav Karsten; Gjertsen, Bjørn Tore. 2005. Mechanisms of apoptosis induction by khat alkaloids in leukaemia cells.
  • Dimba, Elisabeth Anne Okumu; Bredholt, Therese; Gjertsen, Bjørn Tore; Johannessen, Anne Chr.; Vintermyr, Olav Karsten. 2005. Khat- and cathionine-induced apoptosis is modulated by Bcl-2 protein expression.
  • Gjertsen, Bjørn Tore. 2005. Individualizing therapy in acute myeloid leukemia through modulation of signaling networks.
  • Stordrange, Laila; Øyan, Anne Margrete; Gjertsen, Bjørn Tore; Bø, Trond Hellem; Bruserud, Øystein; Kalland, Karl-Henning; Jonassen, Inge. 2005. Discovering candidate genes that distinguish between CML and AML using microarrays.
  • Brustugun, Odd Terje; Fladmark, Kari Espolin; Mellgren, Gunnar; Bøe, Ragnar; Zhivotovsky, B.; Vintermyr, Olav Karsten; Gjertsen, Bjørn Tore; Døskeland, Stein Ove. 1998. Ultrarapid apoptosis induction in a variety of cell types injected with phosphatase inhibitors is mediated through Ca2 /calmodulin dependent protei kinase activity.
  • Gjertsen, Bjørn Tore. 1994. Multiple apoptotic death types induced via separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line.
  • Døskeland, Stein Ove; Gjertsen, Bjørn Tore; Houge, G.; Lanotte, M. 1993. Signal-induced Apoptosis in Myeloid Leukemia. Apoptosis or Programmed Cell Death. From Basic Research to Clinical Application.
  • Gjertsen, Bjørn Tore; Cressey, L. I.; Houge, G.; Lanotte, M.; Døskeland, Stein Ove. 1993. "Cyclic AMP dependent protein kinase and phosphatase inhibitors induces different phenotypic forms of cell death.".
Abstract
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology.
  • Helland, Øystein; Mihaela, P.; Gjertsen, Bjørn Tore; McCormack, Emmet ; Bjørge, Line. 2013. PANOBINOSTAT / CARBOPLATIN DELAY POSTSURGICAL RELAPSE OF OVARIAN CARCINOMA IN AN ORTHOTOPIC MOUSE MODEL. International Journal of Gynecological Cancer. 1 pages.
  • Gavasso, Sonia; Marøy, Tove Helene; Mosleth, Ellen Færgestad; Jørgensen, Katarina Mariann; Nakkestad, Hanne Linda; Gjertsen, Bjørn Tore; Myhr, Kjell-Morten; Vedeler, Christian A. 2012. Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. Journal of Neuroimmunology. 18-19.
  • Helland, Øystein; Popa, Mihaela Lucia; Vintermyr, Olav Karsten; Gjertsen, Bjørn Tore; Bjørge, Line; Mccormack, Emmet Martin. 2012. Establishment of a bioluminescence orthotopic mouse model of ovarian carcinoma: Analysis of tumor growth and response to therapy. Acta Obstetricia et Gynecologica Scandinavica. 16-17.
  • Rizzieri, David A.; Vey, Norbert; Thomas, Xavier; Huguet, Francoise; Schlenk, Richard F; Krauter, Jürgen; Kindler, Thomas; Gjertsen, Bjørn Tore; Blau, Igor W.; Johansen, Malin; Bergeland, Trygve; Gianella-Borradori, Athos; Jacobsen, Tove Flem; Rao, Jianyu; Krug, Utz. 2012. A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. Blood. 2 pages.
  • Tiron, Crina Elena; Gjerdrum, Christine; Høiby, Torill; Maugen, Hallvard; Stefansson, Ingunn Marie; Sandal, Tone; Collett, Karin; Li, Shan; McCormack, Emmet Martin; Gjertsen, Bjørn Tore; Micklem, David Robert; Akslen, Lars A.; Glackin, Carlotta A.; Lorens, James. 2011. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 234-235.
  • Hatfield, Kimberley Joanne; Bedringaas, Siv Lise; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2010. OXYGEN LEVELS INFLUENCE THE CYTOKINE RELEASE PROFILE OF AML CELLS. Experimental Hematology. S119-S119.
  • Skavland, Jørn; Hadziavdic, Kenan; Jonassen, Inge; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2010. Combined epigenetic and signal transduction therapy modulate specific signal transduction patterns in acute myeloid leukemia. Haematologica. 510-510.
  • Wang, Jian; Tsinkalovsky, Oleg; Zhao, P; Prestegarden, L; Li, X; Cormark, E; Gjertsen, Bjørn Tore; Bjerkvig, Rolf; Enger, Per Øyvind. 2009. TARGETING THE TUMOR STROMA: A NOVEL THERAPEUTIC STRATEGY BASED ON SEPARATE ANALYSIS OF THE MALIGNANT AND STROMAL CELL COMPARTMENTS IN BRAIN TUMORS. Neuro-Oncology. 965-965.
  • Gavasso, Sonia; Skavland, Jørn; Gjertsen, Bjørn Tore; Myhr, Kjell-Morten; Vedeler, Christian A. 2008. Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. Journal of Neuroimmunology. 134-135.
  • Wergeland, Line; Oveland, Eystein; Sjøholt, Gry; Bedringaas, Siv Lise; Hovland, Randi; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2008. FLT3 internal tandem duplication involving its libiquitin dependent endocytosis motif suspend modulation by HDM2 and are associated with inferior survival in AML. Haematologica. 10-10.
  • McCormack, Emmet Martin; Haaland, Ingvild; Venås, Gurid; Forthun, Rakel Brendsdal; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2008. Evaluation of combinational therapy of MDM2-antagonist nutlin-3 and HDAC-inhibitor valproic acid in acute myeloid leukemia in vitro and in vivo. Blood. 1024-1024.
  • Erikstein, Bjarte Skoe; Tronstad, Karl Johan; McCormack, Emmet Martin; Schwede, Frank; Berge, Rolf Kristian; Gjertsen, Bjørn Tore. 2007. Synergistic anti-leukemic effect of protein kinase a activator and PPAR7agonist is independent of Bcl-2 status. Blood. 117B-117B.
  • Stapnes, Camilla I; Ryningen, Anita; Hatfield, Kimberley Joanne; Øyan, Anne Margrete; Kalland, Karl-Henning; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. Linking susceptibility to histone deactylase inhibitors and basal gene expression profiles in acute myeloid leukaemia. Experimental Hematology. 77-77.
  • Stapnes, Camilla I; Ryningen, Anita; Hatfield, Kimberley Joanne; Øyan, Anne Margrete; Eide, Geir Egil; Kalland, Karl-Henning; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in the susceptibility to histone deacetylase inhibitors. Haematologica. 112-112.
  • Wergeland, Line; Oveland, Eystein; Sjøholt, Gry; Bedringaas, Siv Lise; Hovland, Randi; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2007. Flt3 mutations in proximity to an ubiquitin dependent endocytosis motif suspend its Hdm2 modulation. Blood. 148B-148B.
  • McCormack, Emmet Martin; Belankov, Alexandre; Mujic, Maja; Couture, Pierre; Gjertsen, Bjørn Tore. 2007. Discrimination and quantification of spectrally similar near-infrared probes by time-domain (TD) optical imaging in acute myeloid leukemia mouse models. Blood. 147B-148B.
  • Parlati, Francesco; Aujay, Monette; Bedringaas, Siv Lise; Demo, Susan; Gjertsen, Bjørn Tore; Goldstein, Eileen; Jiang, Jing; Kirk, Christopher; Laidig, Guy; Lorens, James; Lu, Yan; Micklem, David Robert; Ruurs, Paulina; Shenk, Kevin; Sylvain, Catherine; Sun, Congcong; Woo, Tina; Zhou, Han-Jie; Bennett, Mark. 2007. Anti-tumor activity of immunoproteasome selective inhibitors. Blood. 477A-478A.
  • Øyan, Anne Margrete; Bø, Trond Hellem; Jonassen, Inge; Gjertsen, Bjørn Tore; Bruserud, Øystein; Kalland, Karl-Henning. 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. NBS-nytt. 106.
  • Øyan, Anne Margrete; Ånensen, Nina; Bø, Trond Hellem; Stordrange, Laila; Jonassen, Inge; Bruserud, Øystein; Kalland, Karl-Henning; Gjertsen, Bjørn Tore. 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. International Journal of Molecular Medicine. S65.
  • Bredholt, Therese; Dimba, Elisabeth Anne Okumu; Johannessen, Anne Chr.; Costea, Daniela-Elena; Francis, George W; Vintermyr, Olav Karsten; Gjertsen, Bjørn Tore. 2005. The role of Bcl-2 in apoptosis induced by khat (Catha edulis) in acute myeloid leukemia cell lines. Blood. 195b-195b.
  • Cimpan, Mihaela Roxana; Muna, Ziad Ahmed; Sørnes, Steinar; Gjertsen, Bjørn Tore; Matre, Roald; Skaug, Nils. 2001. Vitamin E prevents apoptosis and necrosis in U-937 cells exposed to eluates from autopolymerized denture base acrylic resins. Journal of Dental Research. 1291-1291.
  • Cimpan, Mihaela Roxana; Skaug, Nils; Gjertsen, Bjørn Tore; Matre, Roald. 1999. Altered clonogenicity and induction of apoptotic cell death in L929 cells exposed to denture base acrylic resins. Journal of Dental Research. 315-315.
  • Cimpan, Mihaela Roxana; Gjertsen, Bjørn Tore; Skaug, Nils; Gjerdet, Nils Roar; Heggø Hansen, Bente; Matre, Roald. 1998. A comparative study of cytopathogenic effects of four denture base acrylic resins. Journal of Dental Research. 816-816.
Academic literature review
  • Andresen, Vibeke; Gjertsen, Bjørn Tore. 2019. Clinical trials of repurposing medicines in acute myeloid leukemia: Limitations and possibilities in the age of precision therapy. 153-163.
  • Andresen, Vibeke; Gjertsen, Bjørn Tore. 2017. Drug Repurposing for the Treatment of Acute Myeloid Leukemia.
  • Gavasso, Sonia; Gullaksen, Stein-Erik; Skavland, Jørn; Gjertsen, Bjørn Tore. 2016. Single-cell proteomics: Potential implications for cancer diagnostics. 579-589.
  • Gjertsen, Bjørn Tore; Schöffski, Patrick. 2015. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. 11-19.
  • Fredly, Hanne Kristin; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2013. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.
  • Tsykunova, Galina; Reikvam, Håkon; Ahmed, Aymen B; Nepstad, Ina; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2012. Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia? 587-603.
  • Gjertsen, Bjørn Tore; Wiig, Helge. 2012. Investigation of therapy resistance mechanisms in myeloid leukemia by protein profiling of bone marrow extracellular fluid. 595-598.
  • Giles, Francis; Mahon, François-Xavier; Gjertsen, Bjørn Tore; Swords, Roman; Labar, Boris; Turkina, Anna; Rosti, Gianantonio. 2012. Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. 1016-1026.
  • Jørgensen, Katarina Mariann; Hjelle, Sigrun Margrethe; Øye, Ola Kristoffer; Puntervoll, Pål; Reikvam, Håkon; Skavland, Jørn; Anderssen, Endre; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2011. Untangling the intracellular signalling network in cancer - a strategy for data integration in acute myeloid leukemia. 269-281.
  • Gjertsen, Bjørn Tore. 2011. Stratification of pediatric acute myeloid leukemia through cancer cell gene-expression profiling. 355-357.
  • Hjelle, Sigrun Margrethe; Forthun, Rakel Brendsdal; Haaland, Ingvild; Reikvam, Håkon; Sjøholt, Gry; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2010. Clinical proteomics of myeloid leukemia.
  • Stapnes, Camilla I; Gjertsen, Bjørn Tore; Reikvam, Håkon; Bruserud, Øystein. 2009. Targeted therapy in acute myeloid leukaemia: current status and future directions. 433-455.
  • Christoffersen, Thoralf; Guren, Tormod K.; Spindler, Karen-Lise Garm; Dahl, Olav; Lønning, Per Eystein; Gjertsen, Bjørn Tore. 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 6-22.
  • McCormack, Emmet Martin; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2008. Review: genetic models of acute myeloid leukaemia. 3765-3779.
  • Kirkeleit, Jorunn; Riise, Trond; Gjertsen, Bjørn Tore; Moen, Bente Elisabeth; Bråtveit, Magne; Bruserud, Øystein. 2008. Effects of benzene on human hematopoiesis. 87-102.
  • Bruserud, Øystein; Ersvær, Elisabeth; Olsnes, Astrid Marta; Gjertsen, Bjørn Tore. 2008. Anticancer Immunotherapy in Combination with Proapoptotic Therapy. 666-675.
  • Hagland, Hanne; Nikolaisen, Julie; Hodneland, Linn Iren; Gjertsen, Bjørn Tore; Bruserud, Øystein; Tronstad, Karl Johan. 2007. Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. 1055-1069.
  • Øyan, Anne Margrete; Bø, Trond Hellem; Jonassen, Inge; Ulvestad, Elling; Gjertsen, Bjørn Tore; Bruserud, Øystein; Kalland, Karl-Henning. 2007. Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in Acute Myeloid Leukemia. 344-354.
  • Ånensen, Nina; Øyan, Anne Margrete; Huseby, Sjur; Kalland, Karl-Henning; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2007. Early gene expression of acute myeloid leukemia in response to chemotherapy. 741-751.
  • Gjertsen, Bjørn Tore; Bredholt, Therese; Ånensen, Nina; Vintermyr, Olav. 2007. Bcl-2 antisense in the treatment of human malignancies: A delusion in targeted therapy. 373-381.
  • Ånensen, Nina; Haaland, Ingvild; D Santos, Clive; Belle, Werner Van; Gjertsen, Bjørn Tore. 2006. Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia. 199-207.
  • Oveland, Eystein; Fladmark, Kari Espolin; Wergeland, Line; Gjertsen, Bjørn Tore; Hovland, Randi. 2006. Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies. 185-198.
  • Sjøholt, Gry; Bedringaas, Siv Lise; Døskeland, Anne Paulus; Gjertsen, Bjørn Tore. 2006. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). 159-170.
  • Bruserud, Øystein; Stapnes, Camilla I; Tronstad, Karl Johan; Ryningen, Anita; Ånensen, Nina; Gjertsen, Bjørn Tore. 2006. Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. 51-68.
  • Bruserud, Øystein; McCormack, Emmet Martin; Gjertsen, Bjørn Tore. 2006. Immunotherapy in chronic lymphocytic leukemia. 185-187.
  • Sjøholt, Gry; Ånensen, Nina; Wergeland, Line; McCormack, Emmet Martin; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2005. Proteomics in acute myelogenous leukaemia (AML): Methodological strategies-and identification of protein targets for novel antileukaemic therapy. 631-646.
  • Hatfield, Kimberley Joanne; Olsnes, Astrid Marta; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2005. Antiangiogenic therapy in acute myelogenous leukemia: Targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. 229-248.
  • McCormack, Emmet Martin; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2005. Animal models of acute myelogenous leukaemia - development, application and future perspectives. 687-706.

More information in national current research information system (CRIStin)